How to overcome the excess ASCVD risk conferred by Lp(a)? - PACE-CME

How to overcome the excess ASCVD risk conferred by Lpa

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Findings of analysis on pediatric FH patients in large global registry
Findings of analysis on pediatric FH patients in large global registry
EAS 2022
Findings of analysis on pediatric FH patients in large global registry
No role of Lp(a) in thrombosis
No role of Lp(a) in thrombosis
EAS 2022
No role of Lp(a) in thrombosis
- Prof. Alberico Catapano, PhD
New oral therapy of CETP inhibition for lipid lowering
New oral therapy of CETP inhibition for lipid lowering
EAS 2022
New oral therapy of CETP inhibition for lipid lowering
- Prof Kausik Ray
Need for a stratified approach to improve treatment of IHD
Need for a stratified approach to improve treatment of IHD
EAS 2022
Need for a stratified approach to improve treatment of IHD
- Prof. Filippo Crea, MD